Dyslipidemia is having an abnormal amount of lipids or fats in the blood.
Lipid profile is obtained from an individual with diabetes mellitus, coronary heart disease, cerebrovascular disease, peripheral arterial disease or other coronary heart disease risk factors or from an individual with family history or clinical evidence of familial hypercholesterolemia.
Plasma lipids are total cholesterol, high-density lipoprotein cholesterol, trigylcerides, and low-density lipoprotein cholesterol.
Evaluation of lipid profile must be performed in parallel with the risk assessment of coronary heart disease.
The ANGPTL3* inhibitor evinacumab significantly lowers LDL cholesterol (LDL-C) levels in patients with homozygous familial hypercholesterolaemia (HoFH) who were already on maximum lipid-lowering therapy, according to the ELIPSE HoFH** study.
The prescription omega-3 fatty acid icosapent ethyl significantly reduces the need for revascularization in patients with elevated triglycerides who were already on statins and were at increased cardiovascular (CV) risk, reveals the latest data from the REDUCE-IT REVASC analysis presented during the SCAI* 2020 Meeting.
Daily intake of sugar-sweetened beverages was associated with elevated triglyceride levels and lower HDL cholesterol levels, both of which are risk factors for cardiovascular disease (CVD), according to the Framingham Heart Study with up to 23 years of follow-up.
Concomitant use of fimasartan and rosuvastatin in patients with hypertension and dyslipidaemia does not appear to be synergistic in increasing concurrent control rate of the diseases, although either drug is effective against the target disease, according to a study.
Evinacumab, a fully human monoclonal antibody inhibitor of ANGPTL3, effectively lowers LDL-cholesterol (LDL-C) levels in patients with homozygous familial hypercholesterolaemia (HoFH) regardless of their LDL receptor (LDLR) function, according to results of a double-blind phase III trial presented at the American College of Cardiology and World Congress of Cardiology virtual meeting (ACC.20/WCC).
In-hospital initiation of the PCSK9* inhibitor evolocumab, on top of high-intensity statin therapy, in the very high-risk, acute phase of ACS** significantly reduced LDL-C levels — so much so that >95 percent of the patients achieved the recommended target levels — compared with high-intensity statin alone, the EVOPACS*** study has shown.
The European Society of Cardiology (ESC) has released five new guidelines at the ESC Congress 2019, recommending an even lower LDL-C* target in patients at very high risk for cardiovascular disease (CVD), and the use of SGLT2** inhibitors and GLP-1*** receptor agonists as first-line treatments in those with diabetes to reduce their CVD risk.
Recently published cardiovascular outcome trials (CVOTs) in patients with diabetes (DM) have led to updates in the management of cardiovascular disease (CVD) in DM patients. These updates were reflected in the 2019 ESC guidelines on diabetes, prediabetes, and CVD, a collaboration between ESC and EASD*.
The once-daily fixed-dose combination of candesartan plus rosuvastatin reduces systolic blood pressure and low-density lipoprotein cholesterol at the same time with no major safety issues, according to the results of a phase III trial. This drug represents a convenient treatment option for patients with coexistent essential hypertension and hypercholesterolaemia.
Icosapent ethyl may reduce the risk of ischaemic stroke in statin-treated patients who have or are at risk of atherosclerosis, according to post hoc findings of the REDUCE-IT* trial presented at ISC 2021.